Nubank's £10B Monzo Talks, AMD's $8.2B World Labs Buy, and Four More Deals

Six transactions disclosed between September 24 and September 30, 2026 carry enough public detail to set side by side. Three are purchases of whole businesses: a regional bank buying a digital small-business lender, a private equity firm taking a public-safety software company private, and a chipmaker buying an artificial-intelligence research lab with its own stock. Two are licences to drugs developed in China. One is a pair of talks that has not produced a deal at all. The week's two largest headline numbers are an approach that has produced no agreement at all and a purchase paid entirely in shares. The entries run below from the largest disclosed value to the smallest.

Brazil's Nubank is in early-stage talks with Britain's Monzo about a combination that would value the London digital bank at between £8 billion and £10 billion, or $10.60 billion to $13.25 billion, Sky News reported on Saturday, September 26. An acquisition is one of two options Monzo's board is exploring, according to the report, which cited a source close to the process; the other is a funding round expected to value the company above £8 billion, with the proceeds earmarked for expansion into mainland Europe. Monzo and Nubank declined to comment. 12

That is the whole of the public record. There is no agreed price, no signing, and no obligation on either side, which matters because the report itself describes two mutually exclusive paths: a sale, or a private round that would keep Monzo independent and fund its own European build-out. 1

London-based Monzo more than doubled its pretax profit in the year to March 31, 2026, to £87.3 million, on revenue that grew to £1.7 billion from £1.2 billion. It was last valued at £4.5 billion, in an employee share sale in October 2024 to investors including Singapore's GIC and StepStone Group. Nubank is listed in New York with a market capitalisation of about $65.5 billion. 1 At the top of the reported range, the price would be more than double Monzo's October 2024 valuation.

AMD said on September 28 that it would acquire World Labs, the AI research company founded by Fei-Fei Li, in an all-stock deal valued at about $8.2 billion. Li joins AMD as executive vice president and chief scientist. The two companies had already formed an inference optimisation and training partnership in 2025, and the acquisition is expected to close before the end of the year, subject to regulatory approval. 349

World Labs is one of the small group of laboratories working on "world models" — systems trained to understand and simulate physical reality rather than text alone. Its first product, Marble, is sold both as a tool for building entertainment experiences and as a way to generate simulated environments for training robots. That second use is the strategic one: training data for general-purpose robots barely exists, so synthetic scenes produced by world models are treated as a prerequisite for the robots and autonomous machines that AMD's chips would run. 3

World Labs framed the decision as a need for scale and proximity to hardware, and AMD framed it as a way to read frontier workloads into its chip roadmap. 39 Both statements describe the same transaction: a semiconductor company paying for a model laboratory's research direction, so that the models and the silicon are designed in the same building. What AMD is buying is a research team and a roadmap input, not revenue.

Novo Nordisk will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for rights to HRS-1596, an experimental weight-loss pill, the Chinese drugmaker disclosed in a filing with the Hong Kong stock exchange on September 29. The structure is $300 million upfront and up to $2.3 billion tied to development, regulatory and commercial milestones. Novo gains development, manufacturing and commercialisation rights everywhere except Taiwan, Macao, Hong Kong and mainland China. 5

HRS-1596 is approved in China to begin Phase 1 trials for weight management and type 2 diabetes, and Novo says it has the potential to be taken once a week — less often than the once-daily oral products now on the market. It is Novo's second GLP-1 deal with a Chinese partner; the company already has one with United Laboratories International. 5

The context is a fight for share in obesity and diabetes that Novo has been losing. Its shares have fallen more than 70% from their record highs, and the company's own chief executive has said pills could take half the weight-loss market by 2030. 5 Analysts were divided on whether this deal changes that: BMO Capital Markets' Evan Seigerman wrote that the transaction is unlikely to shake up near-term competition but could serve as an attractive longer-term pipeline option, while Union Investment portfolio manager Markus Manns told Reuters that Novo needs larger deals with more advanced compounds to change how the market sees it. 5

Merck said on September 28 that it would pay up to $2.13 billion for global rights to SPR2015, an experimental cancer treatment from China's SciBrunch Therapeutics. SciBrunch receives $400 million upfront and is eligible for up to $1.73 billion more in milestone payments. The transaction has already closed, and Merck expects it to produce a $400 million pre-tax charge, about 13 cents a share, in third-quarter 2026 results. 6

SPR2015 is an oral drug candidate targeting KRAS G12D, one of the mutations that drive pancreatic, colorectal and lung cancers. It is still preclinical and has not entered human testing; the supporting data so far comes from laboratory and animal models, where the companies say it reduced tumour growth. 6

The purchase price is small relative to the problem it addresses. Merck's top-selling drug, the immunotherapy Keytruda, loses patent protection later this decade, and Scotiabank analyst Louise Chen wrote that the company has visibility into more than $70 billion of commercial opportunity by the mid-2030s, against Wall Street's estimate of about $33 billion for Keytruda's peak 2028 revenue. Paying $400 million now for an unproven molecule is the cheap end of that trade: most of the $2.13 billion moves only if the drug works. 6

Valley National Bancorp agreed on September 28 to acquire Bluevine, a Jersey City digital banking platform for small businesses, for total consideration of about $340 million, expected to be split roughly 75% cash and 25% Valley common stock. The transaction is expected to close in early 2027, subject to regulatory approvals. 7

What Valley is buying first is funding. Bluevine brings $2.1 billion of digitally sourced deposits, which grew at about a 35% compound annual rate from 2023 through the second quarter of 2026 and come almost entirely from customers who do not borrow from it, making them what the company calls a diversified, relationship-driven source of core funding. It also brings roughly 175,000 active small-business customers and about 180 research and development staff and engineers. 7

Valley, with about $66 billion of assets and more than 220 branches, has funded itself largely through branches and commercial relationships. The bank expects the deal to add about 8% to estimated 2028 earnings per share including synergies, at the cost of about 5% dilution to tangible book value at closing and an earn-back period of about three years. Bluevine's co-founder and chief executive, Eyal Lifshitz, will join Valley as head of small business banking. 7

Transom Capital Group agreed on September 29 to acquire SoundThinking, a Nasdaq-listed public-safety software company, through a tender offer of $8.00 a share in cash plus one non-transferable contingent value right worth up to $3.00 a share — up to $11.00 a share in total. The implied enterprise value is about $114 million on the cash alone and about $159 million if the maximum right is paid. 8

The $8.00 offer is a 46% premium to SoundThinking's closing price on September 28, the last trading day before the announcement. Shareholders owning about 33% of the stock, including Veradace Partners and Gary M. Lauder, have agreed to tender. Closing is expected in the fourth quarter of 2026 and requires a majority of shares to be tendered. 8

The contingent right is written against a specific number. It pays $0.50 a share if revenue from the ShotSpotter and SafePointe products reaches $73.5 million in 2027, then adds $0.05 a share for every $0.5 million above that through $75.5 million, and $0.05 a share for every $0.25 million above $75.5 million through $87 million. 8 The arrangement shifts about a quarter of the maximum price onto a revenue line the company has not yet delivered.

SoundThinking sells to more than 300 customers and has worked with about 2,100 agencies. Its platform includes ShotSpotter, an acoustic gunshot-detection system, a law enforcement search engine, an investigation management system and software that routes patrol resources. 8

Rank the week's six entries by headline value and the largest is a £8 billion–£10 billion approach that has produced no agreement at all, followed by an $8.2 billion purchase paid entirely in AMD shares. Rank the same six by the cash each buyer commits at signing and the order changes: Merck's $400 million is the largest upfront payment in the issue, and it sits on the fourth-largest headline number. 1356

The proportions are the story. Novo Nordisk commits about 12% of its $2.6 billion headline at signing. Merck commits about 19% of $2.13 billion. SoundThinking's public shareholders are certain of only $8.00 of a possible $11.00. The two smallest entries in the issue are the ones with a settled price. A reader comparing deals on headline value alone would rank the week's commitments almost exactly backwards from the way the sellers' bank accounts will. 5678 The split runs through the coverage note's deals as well: Lifecore Biomedical's shareholders receive $6.28 a share at closing against a maximum of $9.67, with the remaining $160 million tied to performance in 2028, 2029 and 2030, and Nanexa's €1.17 billion headline is built from an upfront payment, €615 million of development and regulatory milestones and the balance from sales milestones. 1011

Merck's SPR2015 and Novo Nordisk's HRS-1596 both come from Chinese developers, licensed this week for rights outside that market. The two agreements are the same shape: a modest upfront payment, a large milestone pool, and the buyer taking responsibility for global development. Together they account for $4.73 billion of headline value, out of a little under $27 billion across this issue's six entries counted at the top of their reported ranges. 56

This is not a one-week pattern, and the reporting says so. Reuters notes that AstraZeneca, Merck and Pfizer have all struck rights deals with Chinese developers, and that Pharmcube counts nearly 250 Chinese GLP-1 candidates under development. 5 The cancer treatment at the centre of the week's third-largest biotech transaction, AstraZeneca's $2 billion investment in Summit Therapeutics, was itself licensed from Akeso of China. 12 For a Western buyer facing patent expiries, an equity cheque or a licence fee paid into China is now a standard way to buy time on the pipeline.

This week's purchases all take something that already exists rather than commissioning something new. Valley National is buying $2.1 billion of deposits that grew at about 35% a year, not a new banking product. Transom is buying a software company with more than 300 customers and an installed base in about 2,100 agencies. AMD is buying a research laboratory whose value is the team and the technical direction. 789

The Nubank approach sits alongside a live alternative for Monzo's board: a private round that would fund building that base rather than selling it. 1 The same reasoning runs through two deals in the coverage note: Capitolis is buying a securities lender's client base of asset owners, and AstraZeneca is paying $2 billion for a stake and a collaboration around a drug someone else developed. 1213 Buyers this week were least interested in anything that has to be built.

This issue covers announcement and report dates from September 24 through September 30, 2026 inclusive, and lists entries in descending order of disclosed value. It draws on Reuters, TechCrunch and Sky News reporting, and on the investor newsrooms and announcements published by AMD, Bluevine, SoundThinking and Lifecore Biomedical.

Four transactions that met the size bar were left out to keep the issue at six entries. AstraZeneca agreed to invest $2 billion in Summit Therapeutics, buying preferred shares at the equivalent of $18.36 a common share — an 18.6% premium to Summit's closing price that day — alongside clinical trials combining Summit's ivonescimab with AstraZeneca's cancer treatments. 12 Novo Nordisk signed a licence with Sweden's Nanexa worth up to about €1.17 billion ($1.33 billion) covering long-acting injectable drugs, structured as an upfront payment and €615 million of development and regulatory milestones with the balance in sales milestones. 10 Lifecore Biomedical agreed to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, paying $6.28 a share in cash plus a contingent value right worth up to $160 million in aggregate. 11 Capitolis agreed to buy the securities lender eSecLending for $200 million in cash. 13

Candidates left out for want of a disclosed price: Databricks' purchase of the spreadsheet startup Row Zero, announced September 24, where the terms were not disclosed 14; and 73 Strings' acquisition of the Paris financial technology company Callisto, announced the same day, also undisclosed. 15 HCLSoftware's €9 million purchase of the Croatian automation provider Robotiq.ai cleared the disclosure bar but not the size one. 16

Two transactions closed during the window that this issue leaves out because their agreements were reached earlier: Long Lake completed its $6.3 billion all-cash acquisition of American Express Global Business Travel, at $9.50 a share, an agreement first announced on May 4, 2026 17; and Lexeo Therapeutics completed its acquisition of Mantle Therapeutics, agreed on September 22 for up to $21.3 million. 1819